More generalized myasthenia gravis (gMG) patients who received Ultomiris (ravulizumab) in the Phase 3 CHAMPION MG trial achieved a favorable clinical response to treatment relative to those taking a placebo, according to new trial analyses. The proportion of patients achieving that milestone, according to the Myasthenia Gravis Foundation…
Myasthenia Gravis News is providing virtual coverage of the 2023 Annual Meeting for the American Academy of Neurology taking place April 22-27 in Boston. Stay tuned to this page for all the latest news.
Repeated treatment with under-the-skin efgartigimod had a consistent effect in easing symptoms of generalized myasthenia gravis (gMG), with no new safety issues identified. That’s according to interim data from the Phase 3 extension study ADAPT-SC+ (NCT04818671), which is…
People with generalized myasthenia gravis (gMG) treated with the experimental therapy rozanolixizumab in a clinical trial generally experienced reductions in disease severity scores regardless of disease duration, prior treatments, and initial disease severity, new analyses suggest. Findings were presented by Tuan Vu, MD, of the University of South…
Treatment with Vyvgart (efgartigimod alfa-fcab) over two years was found to safely and effectively ease symptoms of generalized myasthenia gravis (gMG) among participants in an open-label extension study, according to an analysis of new data. “This analysis suggests that long-term efgartigimod [Vyvgart] treatment is well tolerated and…
Treatment with the experimental therapy zilucoplan eased symptoms of generalized myasthenia gravis (gMG) across different subgroups of patients participating in the Phase 3 RAISE clinical trial. Trial data showed treatment effects were consistent, regardless of sex, age, disease duration, prior use of certain treatments, or thymoma status. Findings…